Cortexyme raised $7.6 million from current investors including Pfizer, Takeda Ventures, Lamond Family, Breakout Ventures and Dolby Family Ventures.
“We appreciate the support and enthusiasm
from our current investors represented
by this new funding based on our rapid and efficient
progress to date. This funding enables us to reach
a significant new milestone,” said Casey Lynch CEO of
Cortexyme is a private company based in South San Francisco, California developing therapeutics to alter the course of neurodegenerative and other disorders. Cortexyme is targeting a specific, undisclosed infectious pathogen tied to neurodegeneration in humans and animal models. Proprietary small molecules are currently in preclinical development.